Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06830980 · ClinicalTrials.gov registry record · NA

Transcranial Magnetic Stimulation for Methamphetamine Use Disorder in PLWH

A NA study of HIV and Methamphetamine Use Disorders, sponsored by Gopalkumar Rakesh.

Recruiting
Registry status
NA
Development phase
30
Enrollment target
1
Study location

NCT06830980: Recruiting NA study of HIV and Methamphetamine Use Disorders, sponsored by Gopalkumar Rakesh.

NCT06830980 is a NA study of HIV and Methamphetamine Use Disorders that is actively recruiting participants, run by Gopalkumar Rakesh. The registered enrollment target is 30 participants, below the 440-participant average among 303 other HIV trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06830980, a NA study of HIV and Methamphetamine Use Disorders, is actively recruiting participants, sponsored by Gopalkumar Rakesh.

RECRUITING
Registry status
NA
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to learn more about how accelerated theta burst stimulation affects methamphetamine craving and brain activity. Theta burst stimulation is a unique transcranial magnetic stimulation (TMS) paradigm that is efficient and potent.

Primary Outcome

Measured on the visual analog scale (VAS) Scored 0 to 100 with 0=no craving and 100=the most craving.

Interventions

  • DEVICE continuous theta burst stimulation (cTBS)
  • DEVICE intermittent theta burst stimulation (iTBS)
  • DEVICE Sham TMS

Study Locations (1)

Kentucky

  • UK Department of Psychiatry - Lexington

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2025-03-11
Est. Completion 2026-12-31
Phase NA
Gopalkumar Rakesh

7 total trials

What NCT06830980 shows while recruiting

NCT06830980 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 440-participant average among 303 other HIV trials with a reported enrollment target (93% lower).

The record links to 2 conditions, with HIV appearing as the primary indexed condition, and to 3 interventions - of which continuous theta burst stimulation (cTBS) is the first listed.

NCT06830980 reports a single indexed study location in Kentucky.

Frequently Asked Questions

What is clinical trial NCT06830980 about?

NCT06830980 is a clinical study titled "Transcranial Magnetic Stimulation for Methamphetamine Use Disorder in PLWH". The purpose of this study is to learn more about how accelerated theta burst stimulation affects methamphetamine craving and brain activity. Theta burst stimulation is a unique transcranial magnetic stimulation (TMS) paradigm that is efficient and potent.

What is the current status of trial NCT06830980?

This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2025-03-11. Estimated completion is 2026-12-31.

What conditions does trial NCT06830980 study?

This clinical trial studies the following conditions: HIV, Methamphetamine Use Disorders.

What interventions are being tested in trial NCT06830980?

The interventions under investigation include: continuous theta burst stimulation (cTBS) (DEVICE), intermittent theta burst stimulation (iTBS) (DEVICE), Sham TMS (DEVICE).

Who is sponsoring clinical trial NCT06830980?

This trial is sponsored by Gopalkumar Rakesh, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06830980 being conducted?

This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for HIV

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06830980's enrollment target sits among peer trials

30 264th of 303 higher than 31 of 303 other HIV trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other HIV trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06830980, the US trial registry maintained by the National Library of Medicine. NCT06830980 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.